Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403086 · ClinicalTrials.gov registry record · Phase 2
Pragmatic Trial of Psilocybin Therapy in Palliative Care
A Phase 2 study of Demoralization, sponsored by Charles S. Grob, M.D..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT05403086: Recruiting Phase 2 study of Demoralization, sponsored by Charles S. Grob, M.D..
NCT05403086 is a Phase 2 study of Demoralization that is actively recruiting participants, run by Charles S. Grob, M.D.. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05403086, a Phase 2 study of Demoralization, is actively recruiting participants, sponsored by Charles S. Grob, M.D..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Primary Outcome
The DS-II is a validated, patient-reported outcome assessing demoralization with a 2-week recall period.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Psilocybin
Study Locations (5)
California
- Marin Cancer Care - Greenbrae
- University of California, Los Angeles - Los Angeles
- University of San Francisco - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Maryland
- Sunstone Therapies - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05403086 shows while recruiting
NCT05403086 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Demoralization appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT05403086 lists 5 locations in 2 states (California, Maryland).
Frequently Asked Questions
What is clinical trial NCT05403086 about?
NCT05403086 is a clinical study titled "Pragmatic Trial of Psilocybin Therapy in Palliative Care". This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
What is the current status of trial NCT05403086?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-01-19. Estimated completion is 2027-12-31.
What conditions does trial NCT05403086 study?
This clinical trial studies the following conditions: Demoralization.
What interventions are being tested in trial NCT05403086?
The interventions under investigation include: Ketamine (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05403086?
This trial is sponsored by Charles S. Grob, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403086 being conducted?
This trial has 5 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demoralization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05403086's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI